n | 27 |
---|---|
Admission characteristics | |
 Age in years, mean (SD) | 65 (9.8) |
 Male sex, n (%) | 12 (44.4) |
 BMI in kg/m2, median [IQR] | 29 [26, 33] |
ARDS classification (Berlin criteria) | |
 Severe, n (%) | 7 (26) |
 Moderate, n (%) | 20 (74) |
 Days since onset of COVID-19 symptoms, mean (SD) | 11.88 (5.31) |
 SOFA score, median [IQR] | 7 [7, 8] |
 Charlson comorbidity score, median [IQR] | 2 [2, 3.5] |
 Cumulative fluid balance (24 h) in liters, median [IQR] | − 0.11 [− 0.59, 0.23) |
 IL-6 receptor inhibitors1, n (%) | 23 (85) |
 Dexamethasone, n (%) | 25 (93) |
Comorbidities2 | |
 COPD, n (%) | 0 (0) |
 Heart failure, n (%) | 0 (0) |
 Renal failure, n (%) | 0 (0) |
 Myocardial infarction, n (%) | 1 (3.7) |
Ventilation and gas exchange | |
 PaO2 in kPa, mean (SD) | 9.01 (1.36) |
 PaCO2 in kPa, mean (SD) | 5.53 (1.04) |
 TV/PBW in ml/kg, median [IQR] | 6.1 [5.7, 8.6] |
 PaO2/FiO2 in mmHg, mean (SD) | 136 (40) |
 PEEP in cmH2O, median [IQR] | 10 [8, 12] |
Laboratory measurements | |
 Hemoglobin in mmol/L, median [IQR] | 8.3 [7.7, 8.8] |
 Leucocytes × 109/L, median [IQR] | 10.8 [8.6, 15.0] |
 Thrombocytes × 109/L, median [IQR] | 320 [259, 385] |
 D-dimer in mg/L, median [IQR] | 3.0 [1.6, 5.4] |
 Creatinine in micromol/L, median [IQR] | 91 [62, 111] |
 NTproBNP in pg/ml, median [IQR] | 180 [116, 424] |
PiCCO measurements | |
 EVLW in ml, median [IQR] | 1026 [843, 1176] |
 EVLWi in ml/kg, median [IQR] | 14.5 [12.8, 17.1] |
 PVPI, median [IQR] | 3.2 [2.8, 4.1] |